HOME > Detail View

Detail View

Cancer chemotherapy

Cancer chemotherapy (Loan 3 times)

Material type
단행본
Personal Author
Airley, Rachel.
Title Statement
Cancer chemotherapy / Rachel Airley.
Publication, Distribution, etc
Chichester, West Sussex ;   Hoboken, NJ :   Wiley-blackwell,   c2009.  
Physical Medium
x, 341 p., [8] p. of plates : ill. (some col.), charts ; 25 cm.
ISBN
9780470092545 (HB) 0470092548 (HB) 9780470092552 (PB) 0470092556 (PB)
Bibliography, Etc. Note
Includes bibliographical references (p. [299]-330) and index.
Subject Added Entry-Topical Term
Cancer -- Chemotherapy. Neoplasms -- drug therapy. Antineoplastic Agents -- therapeutic use.
000 01112camuu2200325 a 4500
001 000045647864
005 20110513155449
008 081201s2009 enkadf b 001 0 eng
010 ▼a 2008052079
020 ▼a 9780470092545 (HB)
020 ▼a 0470092548 (HB)
020 ▼a 9780470092552 (PB)
020 ▼a 0470092556 (PB)
035 ▼a (KERIS)BIB000011697568
040 ▼a 211006 ▼c 211006 ▼d 211006 ▼d 244002
042 ▼a pcc
050 0 0 ▼a RC271.C5 ▼b A35 2009
060 1 0 ▼a QZ 267 ▼b A298c 2009
082 0 0 ▼a 616.99/4061 ▼2 22
084 ▼a 616.994061 ▼2 DDCK
090 ▼a 616.994061 ▼b A298c
100 1 ▼a Airley, Rachel.
245 1 0 ▼a Cancer chemotherapy / ▼c Rachel Airley.
260 ▼a Chichester, West Sussex ; ▼a Hoboken, NJ : ▼b Wiley-blackwell, ▼c c2009.
300 ▼a x, 341 p., [8] p. of plates : ▼b ill. (some col.), charts ; ▼c 25 cm.
504 ▼a Includes bibliographical references (p. [299]-330) and index.
650 0 ▼a Cancer ▼x Chemotherapy.
650 1 2 ▼a Neoplasms ▼x drug therapy.
650 2 2 ▼a Antineoplastic Agents ▼x therapeutic use.

Holdings Information

No. Location Call Number Accession No. Availability Due Date Make a Reservation Service
No. 1 Location Sejong Academic Information Center/Science & Technology/ Call Number 616.994061 A298c Accession No. 151299732 Availability Available Due Date Make a Reservation Service C M

Contents information

Table of Contents

Preface.

1. Cancer epidemiology.

1.1 Cancer incidence, prevalence and mortality.

1.2 Childhood cancers.

1.3 Global epidemiology.

2. Histopathology of cancer.

2.1 Introduction.

2.2 Malignant, benign and normal (non-malignant) tissue.

2.3 Cell death.

3. Carcinogenesis, malignant transformation and progression.

3.1 Introduction.

3.2 Chemical carcinogenesis.

4. Molecular biology of cancer: Oncogenes and tumour suppressor genes.

4.1 Introduction.

4.2 Oncogenesis.

4.3 Tumour suppressor genes.

5. Tumour metastasis: A convergence of many theories.

5.1 Introduction.

5.2 Detachment and migration from the primary tumour.

5.3 Intravasation.

5.4 Transport.

5.5 Extravasation.

5.6 Growth of the metastatic tumour mass.

6. Health professionals in the treatment of cancer.

6.1 Introduction.

6.2 Pathology.

6.3 Radiology.

6.4 Role of the surgical oncologist.

6.5 Oncology pharmacy.

6.6 Oncology nursing.

6.7 The NHS Cancer Plan.

7. Principles of cancer chemotherapy.

7.1 Introduction.

7.2 Timing of chemotherapy.

7.3 Biomarkers and their uses.

7.4 Clinical assessment of biomarkers.

7.5 Pharmacogenetics and pharmacogenomics of cancer chemotherapy.

8. Classic anticancer agents.

8.1 Introduction.

8.2 Alkylating agents.

8.3 Antimetabolites.

8.4 Agents derived from natural or semisynthetic products.

8.5 Hormonal anticancer agents.

8.6 Clinically used chemotherapy regimens.

9. The philosophy of cancer research.

9.1 Introduction.

9.2 Structure of cancer research organizations in the United Kingdom.

9.3 Cancer research in the United States.

10. Novel anticancer agents.

10.1 Introduction.

10.2 Target validation.

10.3 Identification and optimization of lead drugs.

10.4 Preclinical pharmacology.

11. Clinical trials.

11.1 Introduction.

11.2 Evaluation of treatment response.

11.3 Assessment of vascularity and angiogenesis by nuclear medicine technology.

12. Tumour hypoxia.

12.1 Introduction.

12.2 Bioreductive drugs.

12.3 Inhibitors of HIF-1 and HIF-1-regulated genes.

13. Antiangiogenic and antivascular agents.

13.1 History of angiogenesis as a therapeutic target.

13.2 Anti-angiogenic drug targets.

13.3 The return of thalidomide.

13.4 Monoclonal antibodies as anti-angiogenic agents.

13.5 The hollow fibre assay as a drug screen for anti-angiogenic drugs.

13.6 Vascular disrupting agents.

14. Tyrosine kinase inhibitors.

14.1 Introduction.

14.2 Tyrosine kinase inhibitors targeting angiogenesis.

14.3 Non-receptor tyrosine kinase inhibitors.

15. Ras inhibitors.

16. Inhibitors of the Akt PKB pathway.

17. Targeting stress proteins: HSP90 inhibitors.

18. The proteasome.

18.1 Introduction.

18.2 The proteasome as a target for novel drug strategies.

18.3 Ubiquitylation as a target.

19. Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR).

19.1 Mammalian target of rapamycin.

19.2 Structure and activation of mTOR.

19.3 Novel anticancer agents targeting mTOR.

20. Telomerase.

21. Histone deacetylase: an epigenetic drug target.

21.1 Introduction.

21.2 HDAC and DNA packaging.

21.3 HDAC inhibitors.

22. Pharmaceutical problems in cancer chemotherapy.

22.1 Manifestation of toxicity.

22.2 Regimen-related toxicity.

22.3 Secondary malignancies.

22.4 Drug resistance.

22.5 Pharmaceutical complications.

22.6 Phlebitis and venous irritation.

22.7 Health and safety.

22.8 National guidance on the safe administration of intrathecal chemotherapy.

23. Oncology pharmacy at home and abroad.

24. Practice exam questions.

25. Bibliography and further reading.

Index.


Information Provided By: : Aladin

New Arrivals Books in Related Fields

Pendzik, Susana (2022)
용태순 (2022)